Only in this way will the current narrative about value creation be subject to greater scrutiny, and statements such as ‘I am a wealth creator’ measured against credible ideas about where that wealth comes from. A pharmaceutical company’s value-based pricing might then be scrutinized with a more collective value-creation process in mind, one in which public money funds a large portion of pharmaceutical
